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Resveratrol Targets Transforming Growth Factor-b2
Signaling to Block UV-Induced Tumor Progression
Kwang Ho Kim1,2,5, Jung Ho Back1,5, Yucui Zhu1, Josh Arbesman1, Mohammad Athar3, Levy Kopelovich4,
Arianna L. Kim1 and David R. Bickers1
Resveratrol (RES) is a potent anti-cancer agent. We have previously reported that RES arrests the growth of
invasive human A431 squamous cell carcinoma (SCC) cells. In this study, we show that oral administration of RES
to highly tumor-susceptible p53þ //SKH-1 mice markedly delayed UV-induced skin tumorigenesis and reduced
the malignant conversion of benign papillomas to SCCs. Transforming growth factor-b2 (TGF-b2) was
predominantly overexpressed in UV-induced SCCs and its expression was diminished in RES-treated SCCs/
skin. In addition to the inhibition of TGF-b2 expression, RES increased the level of epithelial cadherin. This
RES-mediated TGF-b2 downregulation led to the inhibition of both TGF-b2/Smad-dependent and -independent
pathways, and suppressed the invasiveness of A431 cells. Addition of TGF-b2, but not TGF-b1, rescued the
RES-mediated downregulation of p-extracellular signal-regulated kinases 1/2, p-Smad3, and a-smooth muscle
actin. The protein kinase B (Akt) substrate cAMP response-binding protein (pCREB) transcription factor is
known to regulate TGF-b2 expression, and RES treatment decreased phosphorylation of Akt and pCREB.
Expression of constitutively active Akt blocked RES inhibition of CREB and TGF-b2, and rescued RES inhibition of
cellular invasiveness. Our data indicate that RES suppresses UV-induced malignant tumor progression in p53þ //
SKH-1 mice and that RES-inhibited invasiveness of human A431 SCC cells appears to occur, in part, through the
Akt-mediated downregulation of TGF-b2.
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INTRODUCTION
Transforming growth factor-b (TGF-b) is known to drive
tumor progression in epithelial tumors. Its active form is a
25-kDa dimer bound together by a disulfide bond and
hydrophobic interactions (Rahimi and Leof, 2007). It is
overexpressed in both malignant human tumors and various
experimental animal cancers, including squamous cell
carcinomas (SCCs). Overexpression of TGF-b at the early
stages of carcinogenesis appears to be primarily tumor
suppressive, mainly through growth inhibition. However,
during the later stages of carcinogenesis, TGF-b overexpres-
sion drives epithelial–mesenchymal transition (EMT), tumor
progression, and metastasis. Multiple explanations for this
procarcinogenic effect of TGF-b have been proposed,
including loss of adhesion molecules, increased angiogen-
esis, protease activation, and immunosuppression (Han et al.,
2005). It is known that TGF-b signaling pathways can be
Smad-dependent or -independent. The Smad-independent
pathway involves proteins such as TGF-b-activated kinase-1
(Tak1), extracellular signal-regulated kinase (ERK)/mitogen-
activated protein kinases (MAPK), and RhoA (Yue and
Mulder, 2001; Derynck and Zhang, 2003; Davies et al.,
2005; Choi et al., 2007). Additionally, crosstalk occurs
between distinct TGF-b-activated signaling cascades, such
as the MAPK and Smad pathways. For example, ERK1/2,
c-Jun NH(2) terminal kinase (JNK), and p38 MAPK can
modulate Smad signaling by altering the phosphorylation state
of Smad2 or Smad3 (Derynck and Zhang, 2003; Leivonen
et al., 2005). Given the growing evidence supporting the
role of TGF-b in driving tumorigenesis and metastasis, efforts
to target its inhibition could be useful both for understanding
its biological functions and verifying it as a potential target
for the prevention/treatment of invasive cancer.
Resveratrol (RES) is a polyphenolic phytoalexin found in
grapes and other fruits. Numerous studies have verified its
inhibitory effects on multiple cellular and molecular events
linked to tumorigenesis (Baur and Sinclair, 2006; Athar et al.,
2007). These potentially chemopreventive and chemother-
apeutic effects have been demonstrated in all three stages of
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carcinogenesis (initiation, promotion, and progression) in
UVB- and chemically induced skin tumor growth in mice,
(Aziz et al., 2005 and references therein) and numerous
animal models of human cancers (Athar et al., 2007). In A431
cells, RES was specifically shown to induce G1 cell cycle
arrest, accompanying the induction of p21WAF1 cell cycle
inhibitor (Ahmad et al., 2001; Kim et al., 2002). Because
TGF-b signaling may cooperate with other pathways im-
portant to tumor development, we sought to determine the
effects of RES on TGF-b signaling during UV-induced skin
carcinogenesis. Our data demonstrate that RES suppressed
UV-induced SCC tumorigenesis by modulating the TGF-b2
pathway in p53þ //SKH-1 mice, and further show that RES
inhibits human SCC cell invasiveness by downregulating
protein kinase B (Akt)-mediated TGF-b2 expression.
RESULTS
RES suppresses and delays onset of UV-induced SCCs
in p53þ //SKH-1 murine skin
Chronic UV irradiation is a well-defined skin carcinogen
and has been shown to cause signature mutations in the p53
tumor suppressor gene, and the mutational inactivation
of p53 is thought to contribute to SCCs in both humans
and mice (Benjamin et al., 2008). We and others have
previously shown that RES inhibits the growth of A431
human epidermoid SCC cells lacking functional p53 (Ahmad
et al., 2001; Kim et al., 2006). To determine whether RES can
suppress SCC growth in vivo, we generated p53þ //SKH-1
mice, which are known to develop skin tumors at an
accelerated rate compared with wild-type animals. Many of
the tumors in these mice grow more aggressively and exhibit
a poorly differentiated phenotype following chronic UV
irradiation (van Kranen et al., 2005). Importantly, p53þ //
SKH-1 mice do not die prematurely owing to spontaneous
development of internal malignancies.
In all, 31 p53þ //SKH-1 mice were divided into two
groups (group-1, n¼16; group-2, n¼15) and irradiated with
180mJ cm2 UV twice a week for 25 weeks. At 2 weeks
before the first UV irradiation, RES was administered to
group-2 mice by oral gavage (200mg kg1 body weight in
0.5% methylcellulose) three times per week. Control mice
(group-1) were treated with 0.5% methylcellulose suspension
alone and served as age-matched, positive controls. RES
treatment reduced the average number of skin tumors by 43%
at week 22 and the average tumor volume was diminished by
79%, compared with control mice (Figure 1a and b). SCCs
were detectable as early as week 17 in the UV-irradiated/
untreated control animals, whereas carcinoma development
was delayed until week 20 in the RES-treated animals (Figure
1c). Histological assessment revealed that the number of
SCCs in RES-treated mice was 80% less than that in the
UV-only treated control group at week 22 (Figure 1c).
RES decreases TGF-b2 expression in SCCs and in the skin
of p53þ //SKH-1 mice following chronic UV irradiation
Because EMT is critical to tumor progression and metastases,
the delayed growth of SCCs in the RES-treated animals led us
to ask whether this could be explained by interference with
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Figure 1. Resveratrol (RES) treatment suppresses the growth of UV-induced
squamous cell carcinomas (SCCs) in the skin of p53þ //SKH-1 mice.
Average (avg.) skin tumor number (a) and volume (b) per mouse in each group
during UV-induced skin carcinogenesis. Group-1, UV-irradiated
(180mJ cm2, twice a week, n¼ 16); group-2, UV-irradiated/RES-treated
(200mg kg1 body weight, by gavage, three times a week, n¼15).
p53þ //SKH-1 (F14) mouse and PCR genotyping of wild-type and mutant
alleles are shown in the inset in a. (c) Average number of SCCs per mouse.
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modulators of EMT. A central event in EMT is the loss of
expression of epithelial cadherin (E-cadherin), a surface
receptor, that has an essential role in the formation of
adherence junctions and it is often mutated or lost in cancer
cells (Thiery and Chopin, 1999; Thiery, 2003). Skin and SCCs
excised from the RES-treated mice showed increased
immunohistochemical distribution of E-cadherin compared
with UV-irradiated and non-treated skin and SCCs (Figure 2c
and d, respectively). E-cadherin staining was barely detect-
able in UV-induced SCCs harvested from non-treated
control animals (Figure 2b). Imaging analysis of SCCs
(n¼25 per group) harvested from non-treated and RES-
treated animals show a 4-fold increase in E-cadherin level
following RES-treatment (Figure 2e; Po0.01). Furthermore,
TGF-b2 was overexpressed in UV-irradiated skin and UV-
induced SCCs in the p53þ //SKH-1 mice (Figure 2f and g,
respectively). However, RES treatment substantially decreased
TGF-b2 expression in chronic UV-irradiated skin (Figure 2h)
and SCCs (65% reduction, Po0.01; Figure 2i and j),
whereas the effect on TGF-b1 expression was substantially
less (Figure 2k and l). These data indicate that both TGF-b1 and
TGF-b2 are overexpressed in UV-induced murine SCCs and that
treatment with RES may inhibit tumorigenicity and malignant
tumor progression in p53þ //SKH-1 mice by downregulating
TGF-b2 and/or TGF-b2-mediated regulatory proteins.
RES downregulates TGF-b2/Smad-dependent and -independent
signaling pathways in A431 cells
We further investigated the effects of RES on TGF-b2 and its
downstream signaling pathways in human A431 SCC cells.
RES decreased TGF-b2 levels in a time- and concentration-
dependent manner (Figure 3a and b), whereas TGF-b1 was
unaffected (Figure 3a). In RES-treated cells, the levels of
phospho-Smad2/3 (signal transducers that are downstream
targets of TGF-b receptor-I) were decreased dose-depen-
dently, completely abolishing Smad2/3 phosphorylation at a
dose of 100mM (Figure 3a). TGF-b1-mediated EMT has been
attributed to the relocalization and downregulation of cell
contact proteins and cytoskeleton reorganization (stress
fiber assembly), and upregulation of a-smooth muscle actin
(a-SMA). RES treatment substantially reduced a-SMA and
increased E-cadherin expression (Figure 3c). E-cadherin-
deficient SCC cells reportedly manifest circumferential
cortical actin reorganization and actin stress fiber loss (Alt-
Holland et al., 2008). We used fluorescent-tagged phalloidin,
which binds specifically to F-actin, to visualize the actin
skeleton in RES-treated A431 cells. RES-treated A431 cells
displayed a complex network of stress fibers with perimar-
ginal, axially aligned actin bundles (Figure 3j, arrows). In
contrast, untreated A431 cells showed no apparent stress
fibers, but displayed a cortical actin network (Figure 3f).
Interestingly, the cellular distribution of E-cadherin coincided
with that of F-actin. E-cadherin was present cortically in
untreated cells (Figure 3e), whereas after RES treatment, its
distribution resembled that of the actin stress fiber network
(Figure 3i).
TGF-b is also known to activate non-Smad signaling
pathways such as mitogen- and stress-activated kinase
(MAPK). The ERK signaling pathway activation is required
for TGF-b1-mediated EMT in vitro (Xie et al., 2004).
Consistent with this, we also observed phospho-ERK1/2
downregulation (Figure 3c), indicating that RES likely
suppressed both TGF-b/Smad-dependent and -independent
pathways. The addition of TGF-b2 (2 ngml1), but not TGF-
b1, restored the levels of p-ERK1/2, p-Smad3, and a-SMA
(Figure 4). In contrast, p-Smad2 was not restored by the
addition of TGF-b2 (Figure 4), suggesting that additional
mechanisms regulate Smad2 phosphorylation.
RES reduces Akt/cAMP response-binding protein
(CREB)-mediated TGF-b2 expression
TGF-b2 gene transcription is regulated by CREB and
activating transcription factor-1 (Kingsley-Kallesen et al.,
1999). Specific phosphorylation of CREB at serine 133
induces a stable interaction with the coactivators p300 and
the CREB-binding protein, leading to target gene transactiva-
tion (Chrivia et al., 1993). Akt is an anti-apoptotic serine–-
threonine kinase that regulates numerous critical cellular
pathways, including those that drive cellular proliferation and
inhibition of apoptosis (Garcia et al., 2006). Upon activation,
Akt phosphorylates various transcription factors such as
CREB (Du and Montminy, 1998). Because RES decreased
the TGF-b2 transcript level in A431 cells (Figure 5d), we
hypothesized that the mechanistic basis of RES-mediated
TGF-b2 downregulation may be through modulation of
Akt-CREB signaling. In RES-treated A431 cells, the levels of
both phospho-Akt (S473) and phospho-CREB (ser 133) were
decreased dose-dependently, whereas Akt and CREB were
unaffected (Figure 5a). To further assess the effects of RES on
CREB phosphorylation in A431 cells, we stably expressed
constitutively active myristoylated Akt, which bypasses the
requirement for pleckstrin homology domain-mediated
membrane recruitment (Kumar et al., 2003). Akt overexpres-
sion only partially rescued RES-mediated inhibition of CREB
phosphorylation (Figure 5b), suggesting that RES-mediated
inhibition of CREB phosphorylation involves both Akt-
dependent and -independent mechanisms.
RES-mediated suppression of in vitro invasiveness is rescued
by Akt-dependent TGF-b2 upregulation
Loss of E-cadherin is known to be associated with an increase
in the invasive potential of cancer cells. Therefore, we
assessed the invasive capacity of RES-treated A431 cells by
employing cell invasion assays using a Matrigel Matrix (BD
Bioscience, San Jose, CA). RES at 50–100 mm diminished the
invasiveness of A431 cells by 75–90% (Po0.002) compared
with untreated cells (Figure 5c), accompanied by down-
regulation of TGF-b2 but not TGF-b1 (Figure 5d). The
invasive capacity of RES-treated cells increased 2–3-fold in
the presence of constitutively active Akt (Figure 5c).
Furthermore, overexpression of active Akt alone induced
TGF-b2 expression in the absence of RES (Figure 5d, lane 4),
suggesting a direct link between Akt and TGF-b2. Active
Akt was able to overcome the RES-mediated inhibition of
TGF-b2 expression (Figure 5d, lanes 5 and 6). These results
indicate that the growth inhibitory effects of RES are in part
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Figure 2. Resveratrol (RES) decreases UV-induced transforming growth factor-b2 (TGF-b2) expression and increases epithelial cadherin (E-cadherin).
Immunohistochemical distribution of E-cadherin (a–d) and TGF-b2 (f–i) in UV-irradiated skin (UVB skin) and UVB-induced squamous cell carcinomas (SCCs)
harvested from RES-treated or non-treated p53þ //SKH-1 mice. Arrows indicate positive staining for E-cadherin and TGF-b2. Immunohistochemical image
analysis of E-cadherin (e) and TGF-b2 (j) expression in UV-induced SCCs determined using the ImageJ program. In all, 25 SCCs were screened for each
group. *Po0.01. Bar¼ 50mm. (k, l) Immunohistochemcal staining of TGF-b1 in UVB-induced SCCs from non-treated (k) and RES-treated animals (l).
Bar¼50 mm. Enlargement of staining is in the insets.
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mediated by downregulation of Akt-TGF-b2 signaling in
A431 cells.
DISCUSSION
A major challenge in current cancer research is to identify
novel approaches to chemoprevention using non-toxic
natural substances. RES is a natural phytoalexin found in
various dietary constituents, including the skin of red grapes.
We and others previously showed that RES can inhibit cell
cycle progression of A431 cells (G1/S phase) lacking
functional p53 (Ahmad et al., 2001; Kim et al., 2006). In
this study, we show that oral administration of RES to p53þ //
SKH-1 transgenic mice results in suppression of UV-induced
skin carcinogenesis. Specifically, UV-induced SCCs appeared
later in the RES-treated mice, and the malignant conversion of
benign papillomas to SCCs was substantially inhibited. RES
treatment resulted in increased expression of E-cadherin and
decreased expression of TGF-b2 in SCCs.
In probing the mechanism(s) underlying TGF-b2 down-
regulation, we found that RES inhibited both TGF-b2/Smad-
dependent and -independent ERK signaling pathways, and
suppressed the in vitro invasiveness of A431 cells. RES
inhibited TGF-b2 expression, which is known to be regulated
by CREB transcriptional factors. The CREB/activating tran-
scription factor family of transcription factors responds to
various signals that drive the cell proliferation, differentiation,
and adaptive responses (Shaywitz and Greenberg, 1999). In
addition to cAMP-dependent protein kinase A, CREB is a
target of various kinases, including Akt1 and mitogen- and
stress-activated kinase 1, a kinase activated in the p38 MAPK-
and ERK-dependent cascades (Xing et al., 1996; Deak et al.,
1998; Caravatta et al., 2008). RES-mediated Akt1 inhibition
occurred concomitant with decreased CREB phosphory-
lation. Furthermore, by constitutively activating Akt, it
was possible to partially rescue RES inhibition of CREB
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Figure 3. Resveratrol (RES) inhibits both transforming growth factor-b (TGF-b)-mediated Smad-dependent and -independent extracellular signal-regulated
kinase (ERK) 1/2 pathways. (a, c) Western blot of protein extracts prepared from A431 cells treated with the indicated concentrations of RES for 24 hours.
(b) A431 cells treated with 50 mM RES at the indicated time periods. b-Actin (internal loading control), 80 mg per lane. Cellular distribution of epithelial cadherin
(E-cadherin) (e, i) and actin stress fibers (f, j) following RES treatment (50 mM for 24 hours), assessed by indirect immunofluorescence and phalloidin staining,
respectively. (g, k) Merged images of E-cadherin and F-actin; (d, h) 4’,6-diamidino-2-phenylindole staining. (d–g) Non-treated control A431 cells; (h–k)
RES-treated A431 cells. Arrows in i and j represent E-cadherin and actin stress fibers, respectively. Bar¼ 20 mm.
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Figure 4. Transforming growth factor-b2 (TGF-b2) activates extracellular
signal-regulated kinase 1 (ERK1) and Smad3.Western blot of TGF-b2 pathway
components in A431 cells following RES treatment in the presence or absence
of porcine TGF-b1 or TGF-b2 at 2 ngml1. b-Actin (internal loading control),
80mg per lane.
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phosphorylation and TGF-b2 expression, indicating that
RES suppression of TGF-b2 involves downregulation of the
Akt/CREB pathway.
TGF-b is important in modulating tumor progression
(Cui et al., 1996; Han et al., 2005; Valcourt et al., 2005).
At least three TGF-b isoforms have been identified (TGF-b1,
TGF-b2, and TGF-b3). Among these, TGF-b2 overexpression
has been observed in more advanced stages of gastric
carcinoma and is thought to correlate with a poor prognosis
(Vagenas et al., 2007). It has been reported that specific
inhibition of TGF-b2 using an antisense oligodeoxynucleo-
tide prolongs the survival time of patients suffering from
recurrent or refractory malignant gliomas, including two
patients in whom long-lasting complete tumor remission
occurred (Hau et al., 2007). These observations suggest that
identifying effective methods for TGF-b2 inhibition/down-
regulation may be therapeutically efficacious in later stages of
tumor progression. In skin, it is possible that each TGF-b
isoform could have differential effects during various stages of
carcinogenesis. TGF-b1 expression appears to be associated
with a more differentiated tumor phenotype, whereas TGF-b2
expression is more typical of highly malignant and invasive
phenotypes. TGF-b3 expression is enhanced in the stroma
of malignant tumors in subcutaneously growing HaCat
(immortalized human keratinocytes)-ras tumors in nude mice
(Gold et al., 2000). RES reduced TGF-b2 expression both
in vitro and in vivo. It should be pointed out that in contrast to
our data, RES was previously shown to increase the
transcription of the TGF-b2 gene and the TGF-b2 protein
expression, and to activate Smad signaling in an autocrine
manner in the A549 human lung epithelial cell line (Suenaga
et al., 2008). However, lower doses (3–10 mM) of RES were
used in this study, and the effect of these dosages on TGF-b2
induction was not correlated to cell viability or other cellular
functions. In another study, RES (10 mM) inhibited TGF-b2 in
breast cancer cells (Serrero and Lu, 2001). These differential
effects may be because of differences in the RES concentra-
tions used or differential effects in various tissue types. In our
in vitro study, RES downregulated both TGF-b/Smad and
Smad-independent ERK activation. Our data indicate that
RES-mediated inhibition of ERK activation is likely mediated
through TGF-b2, as exogenous addition of TGF-b2 but not
TGF-b1 rescued ERK activation. Interestingly, Smad2 inhibi-
tion was not rescued by the addition of TGF-b2 or TGF-b1,
suggesting TGF-b-independent mechanisms for the RES-
mediated suppression of Smad2 activation. Although TGF-b
signaling is known to promote EMT via both Smad- and non-
Smad-dependent pathways (Zavadil and Bottinger, 2005),
mice with a keratinocyte-specific Smad2 deletion reportedly
have accelerated formation and malignant progression of
chemically induced skin tumors, and Smad2-deficient tumors
exhibit EMT (Hoot et al., 2008). In our studies in A431 cells,
RES had no effect on Smad2. It is not clear in the present
study whether Smad2 deficiency and inhibition of Smad2
phosphorylation have different functions.
EMT blockade offers a potentially novel and effective
approach for the prevention/treatment of cancer, particularly
in lesions with a propensity for metastasis. However,
accelerated EMT may be only a partial determinant of
malignant progression that may require other oncogenic
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Figure 5. Resveratrol (RES) suppresses protein kinase B (Akt)/cAMP response-binding protein (CREB) activation and in vitro invasiveness in A431 cells.
(a) RES inhibits Akt/CREB phosphorylation. Total extracts prepared from A431 cells treated with the indicated concentrations of RES for 24 hours were analyzed
by western blotting. Constitutively active Akt suppresses RES inhibition of CREB phosphorylation (b) and in vitro invasiveness of A431 cells (c). A431 cells
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next to each other have been juxtaposed. Cell invasiveness was assessed in Matrigel-coated chambers. Results from three independent experiments performed in
triplicate are expressed as percent of control. (d) Cells treated as in c were assessed for transforming growth factor-b1 (TGF-b1) and TGF-b2 expression
by reverse transcriptase-PCR. GAPDH served as an internal control.
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events to promote tumor invasion. Other pathways com-
monly activated in late-stage skin carcinogenesis, such as Akt
and NF-kB, are known to enhance EMT (Dong et al., 2007;
Lester et al., 2007; Hoot et al., 2008). Here, we have shown
that RES inhibits Akt-mediated TGF-b2 functional coopera-
tion between cellular growth signaling and TGF-b pathway
regulators, which may enhance EMT. Whether there is a
spatial correlation (i.e., expression in the invasion front)
between TGF-b2/Akt expression and tumor progression, or
whether and how RES specifically targets these cells in vivo
requires further investigation. In summary, our data indicate
that RES is a potent inhibitor of tumor cell growth and may
modulate tumor progression by altering the EMT process by
downregulating TGF-b2.
MATERIALS AND METHODS
Cell lines and reagents
A431 human epidermoid carcinoma cells were obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and
maintained according to ATCC guideline. RES was purchased from
LKT Laboratories (St Paul, MN) and porcine TGF-b1, TGF-b2 from
R&D systems (Minneapolis, MN). pUSEamp-myrAKT1 was obtained
from Millipore (Billerica, MA). A431 cells cultured in 100mm plate
were transfected with pUSEamp-myrAKT1 at 10 mg using lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA) and stable colonies were
selected in the presence of G418 (Sigma-Aldrich, St Louis, MO).
Total RNA preparation and reverse transcriptase-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen). About 2mg
of total RNA and SuperScript III First-Strand Synthesis System
(Invitrogen) were used for the complementary DNA synthesis
reaction according to the manufacturer’s instructions. PCRs were
carried out with the TGF-b1 primer set with forward primer,
50-GGGACTATCCACCTGCAAGA-30 and reverse primer, 50-CAACTC
CGGTGACATCAAAA-30, and the TGF-b2 primer set with for-
ward primer, 50-CCGGAGGTGATTTCCATCTA-30 and reverse
primer, 50-TGCAGCAGGGACAGTGTAAG-30. Human glyceralde-
hyde 3-phosphate dehydrogenase complementary DNA was ampli-
fied with human glyceraldehyde-3-phosphate-dehydrogenase
(hGAPDH) forward primer, 50-TCATTGACCTCAACTACATGGTTT
AC-30 and hGAPDH reverse primer, 50-GGCATGGACTGTGGTC
ATGAGTC-30 to determine the integrity of the RNA and for use as an
internal control.
Western blotting analysis
Western blotting analysis was performed as previously described
(Kim et al., 2002). Antibodies against TGF-b1 and TGF-b2, and
Smad2/3 were from Santa Cruz Biotechnology (Santa Cruz, CA),
p-CREB (S133), p-Smad2 (S465/467) and p-Smad3(S423/425),
p-ERK1/2(T202/Y204), p-Akt(S473), and Akt from Cell Signaling
Technology (Danvers, MA), a-SMA from Sigma-Aldrich and ERK1/2
from Upstate (Lake Placid, NY).
Generation of p53þ //SKH-1 hairless mice
Eight-week-old female non-agouti p53/ mice (B6/C57BL/
6J-Trp53/) were obtained from Jackson Laboratories (Bar Harbor,
ME). These mice were crossed with SKH-1 males (Charles River
Laboratories, Wilmington, MA) to generate littermates heterozygous
for both p53 and hairless alleles. p53þ / hairless SKH-1 mice (F2)
were selected from inter-generation crosses among F1 littermates of
SKH-1 and p53//C57BL/6 genetic background. These mice were
then backcrossed for 11 generations to SKH-1 hairless mice to
minimize the C57BL/6 genetic background, resulting in a colony of
p53þ / hairless SKH-1 mice (F14). Mice were genotyped by PCR for
both wild-type and the knockout gene using specific primers for
p53. The sequences of PCR primers to detect p53 þ /þ , p53 þ /, and
p53 / were obtained from the Jackson Labs).
UV light source
A UV Irradiation Unit (Daavlin, Bryan, OH) equipped with an
electronic controller to regulate the dosage was used. The UV source
consisted of eight FS72T12-UVB-HO lamps that emit UVB
(290–320nm, 75–80% of total energy) and UVA (320–380nm,
20–25% of total energy). We employed a Kodacel cellulose film
(Kodacel TA401/407, Kodak, Rochester, NY) to eliminate UVC
radiation. A UVC sensor (Oriel’s Goldilux UVC Probe, Oriel, Stratford,
CT) was routinely used during each exposure to confirm lack of UVC
emission. The dose of UV was quantified with a UVB Spectrum 305
Dosimeter obtained from the Daavlin . The radiation was further
calibrated with an IL1700 Research Radiometer/ Photometer from
International Light (Newburyport, MA).
Tumor study in p53þ //SKH-1 mice
Animal experiments were performed in accordance with guidelines
of our approved Columbia University Institutional Animal Care and
Use Committee protocol. A total of 31 p53þ //SKH-1 mice were
divided into group-1 (n¼ 16) and group-2 (n¼ 15), and irradiated
with 180mJ cm2 UV twice a week for 25 weeks. At 2 weeks before
the beginning of UV irradiation, RES was administered to mice
in group-2 by oral gavage, 200mg kg1 body weight in 0.5%
methylcellulose (Sigma-Aldrich), three times per week. Control mice
(group-1) were treated with 0.5% methylcellulose suspension alone
and served as age-matched, untreated controls. Mice were killed
at week 25. Their dorsal skin was removed, and tumors were
harvested and collected for histological and immunohistochemical
studies. Immunohistochemical staining was performed as previously
described (LeBel et al., 1992).
Cell invasion assay
A431 cells (5 104 cellsml1) stably transfected with pUSEamp-
myrAKT1 or vector were cultured in the presence of RES in a BD
BioCoat Matrigel Invasion Chamber (BD Bioscience, San Jose, CA).
After 22 hours of incubation in a humidified tissue culture incu-
bator at 37 1C, cells that invaded the lower compartment of the
membranes were stained with toluidine blue and counted with a
Coulter counter. Three independent experiments were performed in
triplicate and the percentage of invasive cells was determined in at
least three fields per experiment.
Image analysis
Images were analyzed using ImageJ public domain software (the
National Institutes of Health, Bethesda, MD; http://rsb.info.nih.
gov/ij/) to calculate area and pixel value statistics of TGF-b2- and
E-cadherin-positive areas. Images obtained from 25 SCCs from
UV-irradiated, non-treated animals and 25 SCCs from UV-irradiated,
RES-treated animals were analyzed.
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Statistical analyses
Statistical analyses were performed using the Student’s t-test (two-
tailed): Po0.05 was considered statistically significant.
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